Financial Data and Key Metrics Changes - The company ended 2025 with a cash balance of $13.4 million, an increase from $4.6 million in 2024, while operating costs decreased nearly 40% over the year [14][19] - The net loss for Q4 2025 was $2.6 million or $0.56 per share, compared to $2.5 million or $0.62 per share for Q4 2024. For the full year, the net loss was $12.5 million or $2.93 per share, compared to $10.8 million or $2.86 per share in 2024 [19] Business Line Data and Key Metrics Changes - MiNK cells are in phase II clinical trials for solid tumor cancers and autoimmune inflammatory conditions, demonstrating durable survival beyond 23 months and complete remission extending beyond two years in heavily pretreated refractory cancers [3][6] - The company is advancing trials in graft versus host disease (GVHD) and severe hypoxemic pneumonia, with significant external funding secured for these initiatives [4][11] Market Data and Key Metrics Changes - The hypoxemic pneumonia market affects approximately 200-300,000 patients annually, with a mortality rate of 30%-40% and no approved disease-modifying therapies [8][10] - The company is targeting a specific patient population for its ARDS trial, utilizing a global ARDS definition to ensure precise selection based on oxygenation and organ function [35] Company Strategy and Development Direction - The company is focused on capital efficiency, combining disciplined internal execution with non-dilutive funding through government and institutional partnerships [5][12] - The strategic approach includes advancing a PRAME-targeted TCR-engineered iNKT program, leveraging collaborations to enhance platform capabilities without significant capital burden [13][14] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of demonstrating durability and mechanistic validation of their technology in 2025, setting the stage for future clinical advancements [21] - The company expects to initiate a randomized phase II/III ARDS study and dosing in the GVHD trial in the first half of 2026, with initial clinical data anticipated in the second half of the year [17][21] Other Important Information - The company has appointed Melissa Orilall as Principal Financial Officer to strengthen financial leadership and ensure alignment in capital allocation and operational execution [15] - The company has secured multiple sources of non-dilutive capital funding, including NIH funding and philanthropic support, to advance clinical programs and expand the pipeline [12][14] Q&A Session Summary Question: Can you discuss the phase II pneumonia and ARDS study, including patient numbers and control arm? - Management indicated that the trial will involve patients treated with standard care, with the MiNK cells added on top, emphasizing the unique ability of the cells to modulate immune function even in the presence of steroids [25][26] Question: What is the status of the second-line gastric cancer trial and when will efficacy data be available? - Efficacy data from the gastric cancer trial is expected to be presented at a major conference in the first half of the year [29] Question: What differentiating aspects does the company consider for IPF and GVHD patient populations? - Management highlighted the immune-related nature of IPF and the potential for MiNK cells to provide benefits, with plans for a responsible funding approach for the trial [30][33] Question: Can you clarify the combination approach with the IL-15 iNKT cell trial? - Management clarified that no formal announcement has been made regarding collaborations with IL-15 superagonists, and any strategic collaborations will be publicly disclosed at the appropriate time [44][45]

Financial Data and Key Metrics Changes - For the fourth quarter, AirJoule Technologies reported net operating expenses of $3.2 million, with full-year net operating expenses at $13.6 million, up from $11.2 million in 2024, primarily due to a $4.2 million increase in non-cash stock-based compensation [28][29] - The net loss for the full year is $9 million, with a loss from investment in AirJoule JV of $39.3 million, compared to $5.3 million for the full year 2024 [29][30] - AirJoule Technologies ended 2025 with approximately $22 million in cash, and after a January 2026 equity offering, the combined cash position across AirJoule Technologies and the JV was approximately $44 million with no debt [31][32] Business Line Data and Key Metrics Changes - The company focused on technology validation, product development, and partnerships, achieving significant milestones in deploying AirJoule systems in various locations, including Texas, Arizona, California, and Dubai [8][9] - The AirJoule Core product, optimized for industrial dehumidification and water generation, is expected to be commercially available in late Q4 2026, while the larger AirJoule Prime system is currently under construction [19][20] Market Data and Key Metrics Changes - The Middle East is highlighted as a critical market due to its water stress, with Gulf nations relying on desalination for 70%-90% of their drinking water, creating a significant opportunity for AirJoule's distributed water generation technology [15][16] - The ongoing geopolitical conflicts have increased the urgency for water resilience, reinforcing the demand for AirJoule's solutions in the region [17] Company Strategy and Development Direction - The company aims to transition to a commercial pipeline in 2026, focusing on securing long-term customer commitments across various sectors, including data centers, industrial, defense, and international markets [13][14] - AirJoule's strategy includes leveraging partnerships, such as with GE Vernova and TenX, to accelerate commercialization and expand market access [11][12] Management's Comments on Operating Environment and Future Outlook - Management emphasized the growing urgency of water resilience due to environmental and geopolitical factors, positioning AirJoule's technology as a solution to these challenges [4][5] - The company expects 2026 to be a pivotal year for building customer relationships and deploying systems that will lay the groundwork for scaled commercial activity in 2027 and beyond [27][71] Other Important Information - The company has established a water purchase agreement business model, which has been well received by customers, and is expected to support long-term gross margins of 30%-35% at scale [50][56] - The company is actively engaged in customer outreach through direct engagement, warm introductions, and participation in conferences and trade shows [38][39] Q&A Session Summary Question: Customer engagement strategies - The company engages customers through direct outreach, warm introductions, and participation in industry events, with a focus on addressing urgent water needs in sectors like data centers [36][39] Question: Supply chain concerns - Most components are commercially available, with the only custom part being the sorbent chamber, which is produced at scale [40][41] Question: Capital expenditure needs for 2026 - The anticipated capital calls for the joint venture are part of the normal funding plan, with no major additional CapEx expected for 2026 [43][45] Question: Expected gross margins - Initial gross margins are less emphasized, with long-term targets of 30%-35% as the company transitions to contract manufacturing [50][51] Question: Competing with desalination - AirJoule's technology offers advantages in speed to market and water quality, despite desalination being cheaper in operating costs [53][54]

Mink Therapeutics (NasdaqCM:INKT) Q4 2025 Earnings call March 31, 2026 08:30 AM ET Company ParticipantsEmily Bodnar - VP of Equity ResearchJennifer Buell - President and CEOMayank Mamtani - Senior Managing Director and Group Head of Healthcare ResearchMelissa Orilall - Principal Financial OfficerStefanie Perna-Nacar - Chief Communications OfficerOperatorGood morning, and welcome to MiNK Therapeutics' fourth quarter and year-end 2025 financial results conference call. All participants will be in a listen-onl ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $32.4 million, a 3% increase from $31.5 million in Q4 2024, despite a $2 million revenue loss due to the early closure of the Companion Spine transaction [4][14] - Full year 2025 revenue reached $133.9 million, representing a 14% growth from $117.3 million in 2024 [7][16] - Adjusted EBITDA for Q4 2025 was $1.9 million, compared to approximately $0.4 million in Q4 2024, while full year adjusted EBITDA was $16.3 million, a significant improvement from a loss of $2.3 million in 2024 [19][16] - Net income for Q4 2025 was $57,000, or $0.00 per share, compared to a net loss of $3.2 million, or $0.02 per share in Q4 2024 [16] Business Line Data and Key Metrics Changes - The biologics product family was essentially flat in Q4 2025, with a focus on high-margin products expected to drive future growth [7][8] - Sales and marketing expenses for Q4 2025 were $10.9 million, down from $11.7 million in Q4 2024, primarily due to reduced commission expenses [15] - Research and development expenses decreased to $459,000 in Q4 2025 from $522,000 in Q4 2024 [15] Market Data and Key Metrics Changes - The company anticipates continued organic growth in its core biologics business, with expectations for revenue in 2026 to be between $95 million and $99 million [12] - The loss of license revenue from Q-Code and amniotic membrane agreements is expected to impact 2026 revenue, but the company is optimistic about ramping up its advanced wound care products [28][29] Company Strategy and Development Direction - The company has sharpened its focus on its core high-margin biologics business following the sale of non-core assets, which is seen as a transformational move [5][6] - Plans to double the number of regional sales representatives and expand the national accounts team are in place to drive institutional adoption and revenue growth [9][12] - The company is committed to maintaining positive free cash flow and does not anticipate the need for additional outside capital [5][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational discipline and the successful execution of strategic initiatives aimed at self-sustainability and cash flow generation [8][12] - The outlook for 2026 includes expectations for sequential quarter-over-quarter growth, driven by new product offerings and an expanded commercial organization [26] Other Important Information - The gross margin for Q4 2025 was 54.9%, an increase from 50.8% in Q4 2024, attributed to a favorable sales mix [14] - The company had $17.3 million in cash equivalents and restricted cash as of December 31, 2025, compared to $6.2 million a year earlier [20] Q&A Session Summary Question: Outlook for 2026 and organic growth in core biologics business - Management expects sequential quarter-over-quarter growth in 2026, with biologics in Q1 anticipated to be down low double digits compared to Q1 2025 due to headwinds from lost amnio product [26][27] Question: Impact of loss of license revenue from Q-Codes - The Q-Code revenue will completely go away, but management anticipates ramping up sales of their own branded products in advanced wound care as the year progresses [28][29] Question: Decline in hardware business throughout 2026 - A slow decline in the hardware business is expected throughout the year, with a projected decline approaching high teens percentage [31] Question: Growth drivers in biologics and distribution channels - Key growth drivers include advanced biologics products like OsteoVive Plus and CollagenX, with approximately 20-22% of growth expected from OEM channels [36][40] Question: Strategic thoughts on hardware business and gross margin in 2026 - Management is evaluating the hardware business as a potential strategic distraction but sees current offerings as strong. Gross margin for 2026 is expected to be in the low 60s percentage [46][48]

Financial Data and Key Metrics Changes - For the full year 2025, revenues reached $427 million, representing a 142% year-over-year increase from the prior year [13] - Gross profit increased by 340% to $96.3 million in 2025, up from $21.9 million in 2024, with gross profit margin expanding to 22.5% from 12.4% in 2024 [13][14] - EBITDA was $95.8 million in 2025, a 40% increase from $68.2 million in the prior year, while non-GAAP adjusted EBITDA was $110.8 million, up by 228% compared to $33.8 million for the same period in the prior year [15] - GAAP net income was $37.2 million for 2025, compared to $40.5 million for the same period last year, while adjusted net income was $52.2 million, compared to $6 million in 2024 [15][16] Business Line Data and Key Metrics Changes - The primary growth driver was a $241 million increase in solar cell sales, with an additional $7.6 million increase in module sales [13] - The company successfully shipped 2.3 gigawatts from Ethiopia to U.S. end customers and 1.9 gigawatts from Vietnam to international markets [6] Market Data and Key Metrics Changes - The company is positioned to meet the accelerating demand in the U.S. solar market, with shipment guidance for 2026 set between 5.5 and 5.8 gigawatts for solar cells and 1 to 1.3 gigawatts for solar modules [10][11] - The operational focus for 2026 includes maximizing existing infrastructure, particularly the Ethiopia cell facility and the Houston module facility [11] Company Strategy and Development Direction - The company aims to scale production continuously in 2026 and invest to expand capacity in Houston to 2 gigawatts [8] - The acquisition of the BridgeSun brand is intended to streamline operations and enhance growth without diluting shareholder value [9] - The company is committed to strengthening its supply chain by migrating sourcing of key components to the U.S. [9] Management's Comments on Operating Environment and Future Outlook - Management highlighted the successful navigation of a volatile trade environment and the establishment of a resilient foundation for future growth [5] - The company anticipates adjusted net income of approximately $90 million to $100 million for 2026, despite significant investments in R&D and technology [12] Other Important Information - The company generated cash flow from operations of $133 million in 2025, with $92 million of CapEx invested in manufacturing facilities [17] - The management team has been strengthened with the appointment of Rhone Resch as Chief Strategy Officer [2] Q&A Session Summary Question: Insights on gross margins with increased U.S. revenue share - Management indicated that they expect to maintain competitive margins as the Ethiopia facility operates at full capacity and the U.S. factory comes online [20][22] Question: Potential credits for Houston production capacity in 2026 - Management is cautious about providing guidance for Houston production but anticipates achieving 60%-70% utilization of the current 1 gigawatt capacity [25][26] Question: Future frequency of earnings calls - The company plans to report quarterly starting this year, with the first quarter numbers expected in May [27]

B.O.S. Better Online Solutions (NasdaqCM:BOSC) Q4 2025 Earnings call March 31, 2026 08:30 AM ET Speaker0Good morning, and thank you for making the time to join our full year 2025 results call. Joining me is Mr. Moshe Zeltzer.Speaker3HelloSpeaker0... our Chief Financial Officer. I am pleased to report that 2025 was an outstanding year for B.O.S. on multiple metrics, and I am grateful to our team for the hard work and commitment in achieving these results. We delivered strong revenue growth throughout the yea ...

Mink Therapeutics (NasdaqCM:INKT) Q4 2025 Earnings call March 31, 2026 08:30 AM ET Speaker4Good morning, and welcome to MiNK Therapeutics' fourth quarter and year-end 2025 financial results conference call. All participants will be in a listen-only mode until the question and answer session. As a reminder, this event is being recorded. If anyone has any objections, you may disconnect at this time. I would now like to turn the conference over to Stephanie Pernicaro, Chief Communications Officer. Please go ah ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $16 million, representing a 4% decline year-over-year primarily due to lower system sales [19] - Full year 2025 revenue increased by 9% compared to 2024, with recurring revenue growing by 15% [21][22] - Gross margin for Q4 2025 was $6.9 million, representing a gross margin percentage of 43%, compared to 42% in Q4 2024 [23] - Full year gross margin was 46%, down from 48% in 2024, attributed to inflationary cost increases and tariffs [24] Business Line Data and Key Metrics Changes - The installed base of ALLY systems grew to approximately 200, up 48% year-over-year, with procedure volume increasing by 20% year-over-year in Q4 2025 [23] - Procedure volumes for the full year 2025 surpassed 206,000 globally, reflecting a 22% growth [23] - U.S. ALLY sales in Q4 2025 included 12 systems, an increase of 1 system from Q4 2024, while international sales dropped significantly [19][20] Market Data and Key Metrics Changes - Market share in the U.S. increased from 14% to 23.4% over 3.5 years, with significant gains from replacing first-generation lasers [10] - The company noted that nearly 50% of new systems in Q4 2025 were sold to femto-naive surgeons, expanding the market for laser-assisted cataract surgery [11] Company Strategy and Development Direction - The company aims to focus on growing procedure volumes and recurring revenue through additional system placements and increased utilization of existing systems [16] - Plans to re-engage with distributors and key stakeholders to regain momentum in international markets following the termination of the acquisition [15] - The company is exploring new market opportunities, including Australia and New Zealand, and intends to expand its presence in Europe and Southeast Asia [52][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to historical operating performance and emphasized the importance of rebuilding momentum over the next several quarters [9][26] - The termination of the merger was viewed as an opportunity to focus on independent growth and capitalize on market opportunities [66] - Management acknowledged the challenges faced during the acquisition process but highlighted the potential for long-term success and value creation [15][66] Other Important Information - The company received a $10 million transaction deposit following the termination of the merger, which will enhance cash flow [8][18] - Adjusted EBITDA for Q4 2025 was positive at $595,000, indicating operational cash flow positivity despite the challenges faced [25] Q&A Session Summary Question: Distributor commentary and growth re-acceleration - Management noted that while initial conversations with distributors have been positive, it will take several quarters to regain momentum in international markets due to previous uncertainties [30][33] Question: U.S. procedure growth and recurring revenue - Management indicated that U.S. procedure growth remains strong, with expectations for continued growth in recurring revenue as the installed base of systems increases [41][43] Question: Operating expenses and future projections - Management confirmed that cash-based operating expenses are expected to increase by no more than 10% in 2026, primarily focused on commercial activities [37][49]

NextPlat (NasdaqCM:NXPL) Q4 2025 Earnings call March 31, 2026 08:30 AM ET Speaker3Certain statements made during this conference call constitute forward-looking statements. These statements include the capabilities and success of the company's business and any of its products, services or solutions. The words believe, forecast, project, intend, expect, plan, should, would, and similar expressions and all statements which are not historical facts are intended to identify forward-looking statements. These for ...

Solesence (NasdaqCM:SLSN) Q4 2025 Earnings call March 31, 2026 08:30 AM ET Speaker3Good day. Thank you for standing by. Welcome to the Solésence fourth quarter and full year 2025 conference call. Today's call is being recorded. During this call, management will make statements that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This conference call may contain stat ...